For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and Attruby represents a true change. These novel therapies preserve the transthyretin protein, halting its destructive build-up and reducing the impact of the disease . Patients are now reporting benefits in their health, o